Latest News
Category: Events
Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is...
Read more
Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...
Read more
Telix today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held...
Read more Telix is pleased to provide a webcast recording of A/Prof Brian Shuch and Dr Colin Hayward, Telix Group Chief Medical Officer. The briefing provided an opportunity for investors to hear...
Read more
ASCO GU (February 16-18, 2023), the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present results of the Phase III ZIRCON...
Read more
Telix is pleased to provide a webcast recording of CEO and MD Dr. Christian Behrenbruch presenting at the J.P. Morgan Healthcare Conference on Wednesday 11 January...
Read more
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November...
Read more
At our recent EANM 2022 symposium, Telix brought together some of the world’s key opinion leaders to discuss the impact that nuclear medicine is having on their field. It was...
Read more
We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24...
Read more